Magenta Therapeutics Inc (NASDAQ:MGTA) insider Jason Gardner sold 4,392 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $15.10, for a total transaction of $66,319.20. Following the sale, the insider now owns 344,820 shares in the company, valued at $5,206,782. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Magenta Therapeutics stock traded down $1.08 on Friday, hitting $12.70. The company’s stock had a trading volume of 151,541 shares, compared to its average volume of 130,484. Magenta Therapeutics Inc has a 52-week low of $5.31 and a 52-week high of $21.00. The firm has a fifty day moving average price of $11.60 and a 200-day moving average price of $12.13. The company has a market capitalization of $562.23 million, a P/E ratio of -4.06 and a beta of 3.24.

Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). As a group, analysts expect that Magenta Therapeutics Inc will post -2.05 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Magenta Therapeutics by 43.0% in the 2nd quarter. BlackRock Inc. now owns 1,623,423 shares of the company’s stock worth $23,944,000 after buying an additional 488,065 shares in the last quarter. Vanguard Group Inc. boosted its stake in Magenta Therapeutics by 75.4% during the second quarter. Vanguard Group Inc. now owns 884,348 shares of the company’s stock valued at $13,045,000 after buying an additional 380,135 shares in the last quarter. State Street Corp boosted its stake in Magenta Therapeutics by 20.0% during the third quarter. State Street Corp now owns 332,151 shares of the company’s stock valued at $3,408,000 after buying an additional 55,436 shares in the last quarter. Citadel Advisors LLC boosted its stake in Magenta Therapeutics by 31.5% during the second quarter. Citadel Advisors LLC now owns 229,066 shares of the company’s stock valued at $3,379,000 after buying an additional 54,847 shares in the last quarter. Finally, Platinum Investment Management Ltd. boosted its stake in Magenta Therapeutics by 7.7% during the second quarter. Platinum Investment Management Ltd. now owns 226,558 shares of the company’s stock valued at $3,342,000 after buying an additional 16,209 shares in the last quarter. Institutional investors and hedge funds own 63.42% of the company’s stock.

Several equities research analysts have commented on MGTA shares. ValuEngine lowered shares of Magenta Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Zacks Investment Research lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. BTIG Research started coverage on shares of Magenta Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $20.00 target price on the stock. Cowen restated a “buy” rating on shares of Magenta Therapeutics in a research report on Monday. Finally, Goldman Sachs Group reiterated a “neutral” rating and issued a $18.00 price objective on shares of Magenta Therapeutics in a research report on Friday, December 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $17.75.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

Recommended Story: What Are Cryptocurrencies?

Insider Buying and Selling by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.